Results 61 to 70 of about 46,339 (291)
Trametinib in Adults with Neurofibromatosis Type 1‐Related Symptomatic Plexiform Neurofibromas
Objective Mitogen‐activated protein kinase kinase inhibitors have shown promising results in treatment of plexiform neurofibromas in neurofibromatosis type 1 patients, but data in adults are limited. The aim of this phase 2 study was to investigate the efficacy and safety of trametinib in adults with neurofibromatosis type 1.
D. Christine Noordhoek +7 more
wiley +1 more source
Background. The change in the level of NT-pro-BNP (N-terminal-pro-Brain Natriuretic Peptide) is now considered as a reflection of the hemodynamic alterations and its circulatory reductions reported early after successful PTMC (percutaneous transvenous ...
Safi Morteza +5 more
doaj +1 more source
Impact of DPP-4 inhibitors on plasma levels of BNP and NT-pro-BNP in type 2 diabetes mellitus
Background Dipeptidyl peptidase-4 inhibitors (DPP-4i) decrease glucose levels by regulating incretin peptides in type 2 diabetes mellitus (T2DM). This study aimed to determine the modulatory effect of DPP-4i on brain natriuretic peptide (BNP) and N ...
Liying Mu +5 more
doaj +1 more source
The interpretation of brain natriuretic peptide in critical care patients; will it ever be useful? [PDF]
The measurement of B-type natriuretic peptide (BNP) is recommended for the diagnosis of decompensated heart failure, the prognosis of chronic heart failure is worse if BNP is increased and studies suggest that BNP is useful to guide therapy.
Dixon, J, Philips, B
core +2 more sources
Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman +2 more
wiley +1 more source
Association of genetic polymorphisms of brain natriuretic peptide with cardiovascular diseases
Currently, natriuretic peptides (including brain natriuretic peptide (BNP)) are widely used in clinical practice as biomarkers for various cardiovascular diseases.
A. Ya. Panarina, G. I. Lifshits
doaj +1 more source
Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH [PDF]
Aim Traditionally, risk stratification in heart failure (HF) emphasizes assessment of high risk. We aimed to determine if biomarkers could identify patients with HF at low risk for death or HF rehospitalization.
Anand +46 more
core +1 more source
Objective High intensity conditioning autologous hematopoietic stem cell transplantation (AHSCT) is standard of care for patients with advanced SSc. The role of reduced intensity conditioning (RIC) prior to AHSCT in this population remains unclear. We conducted this study to determine the long‐term outcomes of RIC AHSCT in SSc patients with cardiac ...
Yonatan Lean +4 more
wiley +1 more source
Brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) are polypeptide hormones released by cardiomyocytes in response to cardiac volume or pressure overload.
I. A. Bondar +3 more
doaj +1 more source
NT-proBNP: A Biochemical Marker of Maternal Complications in Pre-eclampsia [PDF]
Introduction: Elevated serum levels of NT-proBNP (N terminal pro-Brain Natriuretic Peptide) are associated with Pre-Eclampsia (PE) and its complications.
Supriya Kumari +4 more
doaj +1 more source

